Skip to search formSkip to main contentSkip to account menu

BTK Inhibitor BGB-3111

Known as: BGB-3111, BTK-InhB 
An orally available inhibitor of Bruton tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, BGB-3111 selectively binds… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
PF538 GENETIC EVOLUTION PATTERNS IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA TO SECONDARY ACUTE MYELOID LEUKEMIA: AN ANALYSIS OF 36 PAIRED SAMPLES
BTK inhibitors have been shown to be highly active in patients with WM harboring the MYD88 L265P mutation, however lower… 
2019
2019
PF532 INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
2017
2017
Abstract 2010: BTK inhibitor BGB-3111 demonstrates anti-tumor activity in solid tumor models
Background BGB-3111 is a novel, irreversible, second generation BTK inhibitor with better selectivity profile and DMPK property… 
2016
2016
Abstract 4796: BTK inhibitor BGB-3111 synergizes with lenalidomide in MCL models
Background BGB-3111 is a novel, irreversible, second generation BTK inhibitor with better selectivity profile and DMPK property… 
2015
2015
Abstract 5496: Effect of BTK inhibitors on differentiation of human monocyte-derived dendritic cells
Dendritic cells (DCs) are primary antigen-presenting cells (APCs), which process tumor antigen and present it on the cell surface… 
2015
2015
Basal Follicle-Stimulating Hormone or Inhibin B Combined with Age as Predictors of Pregnancy After Treatment by Donor Sperm Insemination.
OBJECTIVE To evaluate the clinical significance of basal reproductive hormones and basal inhibin B (INHB) combined with age on…